Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) - a Phase II Clinical Trial

Background -Older patients (pts) with mantle cell lymphoma (MCL) may exhibit poor functional status and become ineligible for intensive chemo-immunotherapy or stem cell transplantation. The advent of chemotherapy-free therapies are a significant advance in MCL. We investigated the safety and efficacy of combining ibrutinib and rituximab (IR) in previously untreated older pts (age ≥65 years) with MCL in a single center, phase II clinical trial.